Fortress Biotech's Strong Revenue Growth
Fortress Biotech, Inc. (NASDAQ: FBIO) has revealed remarkable financial results for its third quarter. The total net revenue rose by 20.5%, reaching $17.6 million, compared to the previous year. This growth underscores the company’s expanding footprint in the biopharmaceutical sector.
Strategic Acquisitions and Partnerships
In a significant move, Fortress's subsidiary, Checkpoint Therapeutics, was acquired by Sun Pharmaceutical. Fortress received around $28 million during the closing of this deal, alongside potential future earnings via a contingent value right (CVR) and a 2.5% royalty on sales of the therapeutic UNLOXCYT™ (cosibelimab-ipdl).
Updates on Dotinurad Development
Dotinurad, a notable next-generation URAT1 inhibitor making strides in two Phase 3 clinical trials, is being closely watched. The backing of Crystalys Therapeutics with a recent $205 million Series A financing signals strong market confidence in the drug’s safety and efficacy potential.
CEO's Insights on Growth
Lindsay A. Rosenwald, M.D., the Chairman and CEO, articulated that Fortress's recent strategic milestones reinforce their diverse business model and enhance shareholder value.
Recent acquisitions validate Fortress's innovative approach, particularly the Checkpoint acquisition which has positioned the company positively in the market.
Progress in Clinical Trials
The advancement of dotinurad in clinical trials speaks to Fortress's commitment to developing treatments that may revolutionize gout therapy. The outcomes from these trials are highly anticipated.
Updates on Emrosi's Market Performance
Moreover, the successful launch of Emrosi™, the treatment for rosacea, has shown strong commercial performance. Journey Medical Corporation, a subsidiary of Fortress, reported a revenue increase to $17.0 million in Q3 2025, which is a significant climb from $14.6 million during the same quarter last year.
Future Outlook
Fortress aims to continue its disciplined focus on capital allocation and advancement of high-impact assets. The company’s pipeline holds the promise of delivering innovative treatments, thus addressing unmet needs in various therapeutic areas.
Frequently Asked Questions
What is Fortress Biotech's revenue growth in Q3 2025?
Fortress Biotech reported a revenue growth of 20.5%, with total net revenue reaching $17.6 million compared to the previous year.
What recent acquisition did Fortress Biotech announce?
Fortress's subsidiary, Checkpoint Therapeutics, was acquired by Sun Pharmaceutical for around $28 million, with potential future earnings through CVR and royalties.
What are the latest updates on dotinurad?
Dotinurad is advancing in Phase 3 clinical trials and is supported by a significant investment from Crystalys, reflecting confidence in its potential.
How well is Emrosi performing in the market?
Journey Medical, which markets Emrosi, reported a substantial increase in revenue to $17 million in Q3 2025.
What are Fortress Biotech's future plans?
Fortress plans to focus on disciplined capital allocation and the advancement of innovative therapies to meet patient needs.